RxDoctor Payments Data

Donald Zeigler, MD

Geriatric Medicine · Chattanooga, TNNPI 1790700771

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $93 and has fallen 59.3% since, to $38 in 2023.

$288in general payments, 2019–2025

Across 18 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scilex Pharmaceuticals Inc.$64
  • Sanofi-aventis U.S. LLC$44
  • Astellas Pharma US Inc$40
  • Corium, LLC$23
  • Biogen$22
  • Neurocrine Biosciences, Inc.$21
  • plus $73 from 5 others

What the payments were for

  • Food & beverage$288100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$288 in reported general payments places this provider in the 60th percentile of 46 geriatric medicine providers in Tennessee.

See all geriatric medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$82,876
Medicare patients
246
Services billed
1,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban350$183,340
OzempicSemaglutide79$85,620
MounjaroTirzepatide42$52,737
XareltoRivaroxaban99$51,149
LinzessLinaclotide68$39,391
CreonLipase/Protease/Amylase12$32,406
FarxigaDapagliflozin Propanediol81$28,496
MyrbetriqMirabegron51$26,498
JardianceEmpagliflozin42$24,312
Breo ElliptaFluticasone/Vilanterol43$18,003
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$16,872
Spiriva RespimatTiotropium Bromide24$12,042
Combivent RespimatIpratropium/Albuterol Sulfate23$11,845
Tresiba Flextouch U-100Insulin Degludec21$11,149
TrulicityDulaglutide11$10,539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Lumigan$11$75,17894 claims
Astellas Pharma US IncMyrbetriq$40$26,49851 claims
MerckJanuvia$12$9,64113 claims
Scilex Pharmaceuticals Inc.Ztlido$64$4,58813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 46 geriatric medicine providers in Tennessee.

Other geriatric medicine in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →